News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


MSNZ welcomes consultation period for Tysabri and Gilenya

Media release (8 August 2014)

MSNZ welcomes beginning of consultation period for Tysabri and Gilenya as proposed new first-line treatments for relapsing remitting forms of Multiple Sclerosis.

The Multiple Sclerosis Society of New Zealand (MSNZ) welcomes PHARMAC’s release of a consultation document today that proposes Natalizumab (Tysabri)and Fingolimod (Gilenya) as potential new first-line treatments for relapsing, remitting forms of MS.

PHARMAC is seeking feedback on a funding proposal involving five treatments for multiple sclerosis (MS), including these two new treatments. It is also seeking feedback on potential changes to the currently funded treatments Avonex, Betaferon and Copaxone.

In February, PTAC (the Pharmaceutical Technical Advisory Committee) recommended to PHARMAC that these new treatments be funded as new first-line treatments.

“It has been a long process to get to this point but PHARMAC’s announcement is a positive step,” says MSNZ spokesman Neil Woodhams. “Relapsing Remitting MS is one of four types of MS, affecting the highest percentage of patients. These new treatments, if accepted by PHARMAC, will be given as soon after diagnosis as possible, to patients fitting within the criteria. This is a great start for all those who will benefit from these treatments.”

Subject to a positive outcome from its consultation process, PHARMAC has suggested that Natalizumab and Fingolimod could be listed on the Hospital Medications List by 1 November 2014 and that changes to the restrictions around access to treatments that are currently funded could also be made by that date.

“This is not the end of the process,” says Mr Woodhams. “The next stage of consultation begins today. We recommend that interested parties read the consultation documents carefully as there are restrictions on the access to these treatments and changes that will be made to the currently-funded treatments.”

Submissions on PHARMAC’s consultation document close on 29 August, 2014.

“MSNZ would like to thank everyone involved in the Patients’ Steering Group, the MS Community, neurologists and supporters who have helped to highlight the importance of funding these new first-line treatments. MSNZ has been overwhelmed with the support and commitment shown to date and we urge supporters to maintain their level of engagement during the next stage of the process and beyond.”

More information about the consultation documents:
For more information visit the PHARMAC website:

Details of the proposal, including proposed funding access criteria, and some background information can be found at:

Please note: The fingolimod component of this proposal is dependent on a multi-product provisional agreement with Novartis, for a number of other products including fingolimod, being approved. PHARMAC are consulting on the Novartis multiproduct proposal separately, see PHARMAC’s website at:

About MSNZ:
For more information about MSNZ please email or call 0800 MS LINE (67 54 63).

© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Howard Davis: Review - A Girl Named Mo

Moana Ete brought her three-piece band A Girl Named Mo to Wellington's intimate and iconic Bats Theatre last week for a five-night residency. Each show was recorded and filmed live for the release of her debut album 'Platonic/Romantic' on Loop records later this year. More>>

For The Birds: Who Will Be Crowned Bird Of The Year?

The competition involves well-known and enthusiastic New Zealanders acting as ‘campaign managers’ for their favourite birds with many going to great lengths to get New Zealanders to vote for their chosen bird... More>>


  • Image Out-Link - Giselle Clarkson on Twitter
  • Gordon Campbell: On Bob Dylan's Nobel (And The Surplus)

    So Bob Dylan has just won the Nobel Prize for… Literature? Wow. I’d be just as happy if he’d won for his work on particle physics (“One Grain of Sand”, “Simple Twist of Fate”) or got the Economics prize for his work on the theory of contracting (“Don’t Think Twice Its Alright”) ... More>>


    Scoop Review Of Books: Whose Goat Was That?

    Mysterious Mysteries of Aro Valley is a sharp, satirical and sometimes downright scary romp through and around that valley in ways that made me question the realities of the places I thought I knew so well. More>>


    NZ On Air TV Funding: More Comedy Comes Out Of The Shadows

    Paranormal Event Response Unit is a series conceived by Jemaine Clement and Taika Waititi as a TV spin-off from their highly acclaimed feature film What We Do In The Shadows. More>>


    Mars News: Winners Announced For The 2016 Apra Silver Scroll Awards

    Wellington singer-songwriter and internationally acclaimed musician Thomas Oliver has won the 2016 APRA Silver Scroll Award with his captivating love song ‘If I Move To Mars’. More>>


    Get More From Scoop



    Search Scoop  
    Powered by Vodafone
    NZ independent news